Want to see IN:AJANTPHARM full AI Analyst Report?
AJANTPHARM Stock Chart & Stats
₹3366.45
₹16.60(0.49%)
At close: 4:00 PM EDT
₹3366.45
₹16.60(0.49%)
Day’s Range― - ―
52-Week Range₹2,335.00 - ₹3,598.40
Previous CloseN/A
Volume81.90K
Average Volume (3M)2.10K
Market Cap
₹433.54B
Enterprise Value₹346.33K
Total Cash (Recent Filing)₹6.65B
Total Debt (Recent Filing)₹2.60B
Price to Earnings (P/E)38.1
Beta0.40
Next Earnings
Nov 04, 2026EPS Estimate
24.05Next Dividend Ex-DateN/A
Dividend Yield0.81%
Share Statistics
EPS (TTM)84.53
Shares Outstanding124,935,620
10 Day Avg. Volume2,991
30 Day Avg. Volume2,099
Financial Highlights & Ratios
PEG Ratio2.23
Price to Book (P/B)7.74
Price to Sales (P/S)6.43
P/FCF Ratio231.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)98.72
Revenue Forecast (FY)₹62.67B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives Ajanta durable financial flexibility to fund organic growth, manufacturing capacity and selective M&A without stressing liquidity. A conservative balance sheet increases resilience to industry shocks, supports reinvestment and preserves strategic optionality over months.
Steady Revenue GrowthConsistent top-line expansion (~11% in FY2026) reflects durable demand for its branded generics and effective commercial execution. Persistent revenue growth supports scale economies, underpins operating leverage and provides a base for margin recovery and sustained reinvestment over the medium term.
Branded Generics Model & Diversified MarketsThe branded generics model plus in-house manufacturing and a mix of direct and distributor channels creates durable competitive advantage: steady demand, control over quality/costs and geographically diversified revenue, reducing reliance on any single market and supporting sustainable margins.
Bears Say
Weakened Cash ConversionMaterial weakening in cash conversion and sharply lower free cash flow versus prior year introduces persistent unpredictability in cash available for capex, dividends or acquisitions. Working-capital volatility reduces financial visibility and limits near-term strategic flexibility until normalized.
Margin Compression In FY2026Notable gross- and operating-margin compression in FY2026 suggests structural pressures—cost inflation, adverse mix or pricing challenges. If persistent, lower margins will erode free cash flow and ROE, making it harder to finance growth and preserve profitability without operational or pricing remedies.
Debt Uptick Watch ItemAn uptick in debt, even from a low base, reduces the company's conservative cushion. Combined with weaker cash conversion, higher borrowings raise refinancing and interest risks and constrain balance-sheet flexibility for capex or M&A until cash generation stabilizes.
Ajanta Pharma Limited News
AJANTPHARM FAQ
What was Ajanta Pharma Limited’s price range in the past 12 months?
Ajanta Pharma Limited lowest stock price was ₹2335.00 and its highest was ₹3598.40 in the past 12 months.
What is Ajanta Pharma Limited’s market cap?
Ajanta Pharma Limited’s market cap is ₹433.54B.
When is Ajanta Pharma Limited’s upcoming earnings report date?
Ajanta Pharma Limited’s upcoming earnings report date is Nov 04, 2026 which is in 90 days.
How were Ajanta Pharma Limited’s earnings last quarter?
Ajanta Pharma Limited released its earnings results on Jul 30, 2026. The company reported ₹26.72 earnings per share for the quarter, beating the consensus estimate of ₹23.04 by ₹3.68.
Is Ajanta Pharma Limited overvalued?
According to Wall Street analysts Ajanta Pharma Limited’s price is currently Overvalued.
Does Ajanta Pharma Limited pay dividends?
Ajanta Pharma Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.81%. See more information on Ajanta Pharma Limited dividends here
What is Ajanta Pharma Limited’s EPS estimate?
Ajanta Pharma Limited’s EPS estimate is 24.05.
How many shares outstanding does Ajanta Pharma Limited have?
Ajanta Pharma Limited has 124,935,620 shares outstanding.
What happened to Ajanta Pharma Limited’s price movement after its last earnings report?
Ajanta Pharma Limited reported an EPS of ₹26.72 in its last earnings report, beating expectations of ₹23.04. Following the earnings report the stock price went up 0.935%.
Which hedge fund is a major shareholder of Ajanta Pharma Limited?
Currently, no hedge funds are holding shares in IN:AJANTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ajanta Pharma Limited
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
―
Wockhardt Limited
―